Insmed told investors at the Jefferies London Healthcare Conference that 2025 has been transformational after FDA approval and launch of Brensocatib, which generated $28 million in its initial partial quarter but may include inventory build, and management reiterated ambitions for Brensocatib to reach >$5 billion peak sales in bronchiectasis while pursuing label and indication expansion (CRS readout by year-end/early January). The company also reaffirmed ARIKAYCE guidance of $420m–$430m, expects a European approval and launch next year that—together with a positive ENCORE readout in H1—could expand the addressable ARIKAYCE population from ~30,000 to ~250,000, and highlighted TPIP’s best‑in‑class phase‑2 PAH data (35.5% PVR reduction) as the catalyst for planned phase‑3 programs across PAH, PH‑ILD, IPF and PPF (TPIP modeled at up to $7bn peak sales). Insmed is well‑capitalized, targeting cash‑flow positivity as commercial revenue ramps, but near‑term upside depends on true demand versus inventory effects, payer access/pricing decisions, and multiple upcoming data readouts that will materially re‑rate the opportunity if positive.
Insmed reported $28 million of initial revenue from the partial-quarter launch of Brensocatib, but management explicitly cautioned that a portion may reflect pharmacy inventory build; ARIKAYCE guidance was reiterated at $420 million–$430 million with European approval anticipated by year-end and Japan contributing roughly 20%–30% of revenue. Management highlighted commercialization momentum with broad prescribing beyond centers of excellence while stressing payer access and final pricing decisions remain pending and will be material for uptake. Management projects Brensocatib could reach >$5 billion peak sales in bronchiectasis and is targeting CRS readout by year-end/early January and an ENCORE readout in H1 next year that could expand ARIKAYCE’s addressable U.S. population from ~30,000 to ~250,000; TPIP showed a 35.5% PVR reduction in phase 2 and is being positioned for phase 3 across PAH, PH-ILD, IPF and PPF with modelling of up to $7 billion peak sales. The company is well capitalized, pursuing multiple clinic launches (gene therapies and DPP-1 portfolio) and aiming for cash-flow positivity, but timing is unspecified. Near-term valuation is binary and driven by (1) real-world sales trends once inventory normalizes, (2) payer coverage/pricing outcomes (including MFN implications in Europe), and (3) the upcoming CRS, ENCORE and TPIP data readouts that will materially re-rate probability of large-market penetration.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
